BMS-299897 has been used as an γ-secretase inhibitor to stop high glucose (HG) mediated amyloid β-peptide (Aβ) secretion.[1]
Actions biochimiques/physiologiques
BMS-299897 is a gamma-secretase inhibitor
BMS-299897 is a potent inhibitor of γ-secretase. The comound is 15-fold more selective for inhibiting the cleavage of β-amyloid precursor protein over Notch cleavage (IC50s 7.1 and 105.9, respectively). In vivo, BMS-299897 blocks the formation of Aβ40 and Aβ42 in the brain and CSF without affecting maturation of CD8+ T cells or intestinal goblet cells, suggesting Notch signalling was not significantly inhibited.
BMS-299897 may be used as a therapeutic for Alzheimer′s disease.[2]
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Amyloid beta-peptide (Aβ), the main component of senile plaques in the Alzheimer's disease (AD) brains, is generated from sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretase. Hyperglycemia in diabetes may compromise barrier integrity in endothelial cells (ECs).
Current drug metabolism, 7(8), 883-896 (2006-12-16)
BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease. The metabolism of [(14)C]BMS-299897 was investigated in human liver microsomes, in rat, dog, monkey and human hepatocytes and in bile duct cannulated rats. Seven metabolites (M1-M7)
Questions
Reviews
★★★★★ No rating value
Active Filters
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..